Cardiac Biomarkers Troponin
Cardiac Biomarkers Troponin - Related Videos
09:23
Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
0 Views •
Cited by 2 •
2017
This work describes a nanoimprinting lithography method to fabricate high-quality sensing arrays that work on the principle of extraordinary optical transmission. The biosensor is low-cost, robust, easy to use, and can detect cardiac troponin I in serum at clinically relevant concentrations (99th percentile cutoff ∼10-400 pg/mL, depending on the assay).
01:20
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
0 Views •
2025
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging. The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include: Troponins Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
10:12
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
0 Views •
Cited by 16 •
2013
Measuring biomarkers in complex biological samples is increasingly guiding clinical decision-making. We describe a highly sensitive method to simultaneously measure cardiac myosin binding protein-C, creatine kinase MB, and cardiac troponin I in serum samples from subjects with myocardial infarction and healthy control subjects.
04:40
Creation of Cardiac Tissue Exhibiting Mechanical Integration of Spheroids Using 3D Bioprinting
0 Views •
Cited by 55 •
2017
This protocol describes 3D bioprinting of cardiac tissue without the use of biomaterials. 3D bioprinted cardiac patches exhibit mechanical integration of component spheroids and are highly promising in cardiac tissue regeneration and as 3D models of heart disease.
07:40
Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
0 Views •
Cited by 3 •
2019
Here, we present protocols of high-intensity interval and moderate-intensity continuous exercise to observe the response of circulating cardiac troponin T (cTnT) concentration to acute exercise over 10 days. The information may assist with clinical interpretations of post-exercise cTnT elevation and guide the prescription of exercise.
FAQs
High-sensitivity assays make cardiac troponin useful for detecting small concentrations and tracking changes across measurements. A single value shows the measured concentration at one time, whereas serial testing can reveal whether the result is rising or changing. That temporal pattern adds clinical information when clinicians assess suspected acute coronary syndrome and helps support earlier diagnostic decisions.
An elevated cardiac troponin result signals myocardial injury, but it does not by itself establish myocardial infarction. The underlying cause must be considered through the broader clinical assessment, including symptoms, electrocardiographic findings, and imaging. This distinction prevents clinicians from treating the biomarker concentration as a stand-alone diagnosis and supports more accurate interpretation of abnormal results.
Serial change provides a time-based perspective on myocardial injury. Comparing measurements can show whether cardiac troponin is rising, rather than relying only on whether one concentration is elevated. Clinicians use this pattern with the rest of the evaluation to strengthen assessment of suspected acute coronary syndrome and to guide the interpretation of laboratory findings.
Cardiac troponin results should be interpreted alongside symptoms, electrocardiographic findings, and imaging. Each source contributes different clinical information, allowing clinicians to place the biomarker result within the patient's overall presentation. This combined approach helps distinguish acute myocardial infarction from other causes of myocardial injury and reduces reliance on laboratory data alone.
The evaluation includes measuring cardiac troponin in blood and comparing results obtained over time. Clinicians examine both the measured concentration and its serial change, then relate those findings to symptoms, electrocardiographic findings, and imaging. This workflow supports a more informed assessment of suspected acute coronary syndrome than interpreting a single laboratory result in isolation.
Cardiac troponin biomarkers support several decisions in suspected acute coronary syndrome. Their results can contribute to earlier diagnosis, risk stratification, and treatment planning when interpreted with the broader clinical assessment. Because an elevated value does not identify the underlying cause by itself, these decisions depend on integrating the biomarker pattern with other available findings.